Sources: U.S. Food and Drug Administration (FDA) Compounding and the FDA (503A & 503B guidance) FDA warning letters on unapproved peptide products National Institutes of Health (NIH) PubMed FDA's Overreach on Compounded Peptides The Peptide Moment: How FDA's Regulatory Reversal Creates Risk and Opportunity for Venture Capital and Private Equity Guidepost Solutions From 'Wolverine' healing claims to health warnings: The unregulated rise of peptides ABC7 Los Angeles